MSD is trying to contribute a lot to overcoming the COVID-19 pandemic. Molnupiravir is fully prepared to be supplied on the same day as soon as it is approved. Kevin Peters, CEO of MSD Korea, made the remarks at a press conference held on the 16th.

MSD developed the COVID-19 treatment Molnupiravir last year and received the U.S. Food and Drug Administration (FDA) EUA in December of that year. This is the second COVID-19 treatment after Pfizer's Paxlovid.

13 countries, including the UK, Japan, Australia and Taiwan, approved the use of Molnupiravir. The WHO has included Molnupiravir as a treatment option in the revised COVID-19 treatment guidelines.

In November last year, MS